Scancell Holdings Plc Equity Research & Stock Reports

Equity Research, Broker Reports, and media content on Scancell Holdings Plc

Access the latest forecasts, broker valuations, multiples, and video content from the city about Scancell Holdings Plc
See live updates from analysts, company announcements, and other news in a personalised/single dashboard

31 Jan 24

Scancell: Heading into important 2024 clinical catalysts

Scancell has a number of important clinical catalysts upcoming in 2024 for its lead cancer vaccines, which are the strategic focus. Readouts include further Phase II data for SCIB1 in advanced skin cancer, first clinical data with second-generation iSCIB1+, and key CPI combination data for Modi-1 in multiple solid tumours. Commercial prospects for these will likely be maximised through partnerships, and positive data could catalyse interest and discussions, in our view. In addition, Scancell’s a

Companies: Scancell Holdings Plc

Trinity Delta

01 Dec 23

Hybridan Small Cap Feast - 01/12/23

1st December 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje

Companies: VANL TRAC SCLP SCLP RBW KIBO CML ADME

Hybridan

01 Dec 23

Trinity Delta Lighthouse: Scancell

Trinity Delta view: Scancell’s successful upsized >£10m placing removes financial uncertainty and, assuming similar success in the Open Offer, means the cash runway now extends to late 2025. This covers the important clinical milestones for both SCIB1 and Modi-1 programmes and could be extended further through the partnering or out-licensing of selected programmes from the GlyMab and AvidiMab antibody platforms. As usual in such situations we suspend our valuation and forecasts, but for context

Companies: Scancell Holdings Plc (SCLP:LON)Scancell Holdings Plc (SCLP:LON)

Trinity Delta

31 Oct 23

Hybridan Small Cap Feast - 31 Oct 23

31st October 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje

Companies: ARV SCLP FIPP KMK KP2 CHAR

Hybridan

31 Oct 23

Trinity Delta Lighthouse: Scancell

Trinity Delta view: Scancell’s cash runway extends to early 2025, covering important clinical milestones for both SCIB1 and Modi-1 programmes. The highly impressive initial SCOPE data effectively demonstrate the value of the SCIB vaccine in combination with CPIs, suggesting results from the second stage (due in H124) could be similarly positive. Early clinical data from the Modi-1 ModiFY study will also be available in 2024. Encouraging clinical outcomes would validate both the ImmunoBody and Mo

Companies: Scancell Holdings Plc (SCLP:LON)Scancell Holdings Plc (SCLP:LON)

Trinity Delta

19 Sep 23

Scancell CEO hails "exciting" high response rate to melanoma treatment

19 Sep 23

Trinity Delta Lighthouse: Scancell

Trinity Delta view: Although a small patient population, these highly impressive data from the SCOPE study effectively demonstrate the concept of using the SCIB vaccine in combination with CPIs. The strength of the results mean the second stage of the study, treating a further 27 patients (bringing the total to 43), has a 90% probability of success. In parallel, a new patient cohort will examine the same CPI doublet in combination with iSCIB1+, which offers broader patient applicability and grea

Companies: Scancell Holdings Plc (SCLP:LON)Scancell Holdings Plc (SCLP:LON)

Trinity Delta

05 Sep 23

Scancell: Upcoming SCIB1 data could provide first proof of concept

Scancell has several key clinical data points due through to end-2024. First data will be from the Phase II trial of SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced skin cancer. If successful the study will transition to the enhanced iSCIB1+ formulation that offers greater potency and broader applicability. If SCIB1 promising early data mature as hoped, then this programme could improve current outcomes. Top-line Modi-1 CPI combination data in multiple tumours are expected in

Companies: Scancell Holdings Plc

Trinity Delta

21 Feb 23

Scancell: Modi-1 successful in first part of Phase I/II trial

Scancell’s Modi-1 has successfully completed the monotherapy arm of the ModiFY Phase I/II trial, generating important results for the Moditope oncology vaccine platform. The first element of ModiFY showed Modi-1 was safe and well tolerated. There were encouraging, albeit early, signals of efficacy despite the advanced disease status of all patients. 23 patients have been treated to date, with 14 patients evaluated; of these 14, one has had a partial response and seven have stable disease. These

Companies: Scancell Holdings Plc

Trinity Delta

15 Feb 23

Scancell: A leader in antibody and vaccine oncology platforms

Scancell is a clinical stage immunology specialist. It has two promising oncology vaccine platforms, Moditope and ImmunoBody, and two antibody technologies, GlyMab (anti-glycans) and AvidiMab, with the potential to treat many solid cancers, either as monotherapy or in combination. Modi-1, the first Moditope programme, is progressing in a Phase I/II trial targeting hard-to-treat tumours with results due through 2023. The lead ImmunoBody programme, currently SCIB1, is in a Phase II study in metast

Companies: Scancell Holdings Plc

Trinity Delta

13 Feb 23

Hybridan Small Cap Feast - 13 Feb 23

13 February 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objec

Companies: BIDS BRCK MKA SCLP SHG MYX

Hybridan

28 Oct 22

Hybridan Small Cap Feast 28/10/22

Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Ithaca Energy, a UK independent exploration and production company focused on the UK North Sea, intends to join the Premium Segment of the Main Market. Ithaca Energy is one of the largest independent oil and gas companies in the UKCS, ranking 2nd by resources and 3rd by production. The offer will initially comprise new ordinary shares and the proceeds will be used to repay existing shareholder debt, includ

Companies: PHC AGY IOF SCLP LIKE EMH

Hybridan

28 Oct 22

Trinity Delta Lighthouse: Scancell

Trinity Delta view: The four technology platforms split neatly into therapeutic vaccines, ImmunoBody and Moditope, and antibodies, GlyMab (anti-glycan mAbs) and AvidiMab. Vaccines are the most advanced, with clinical efficacy data expected during the next 12 months for both lead Moditope and ImmunoBody programmes. The £46.1m raised in FY21 allowed management to finally progress these novel inter-related technology platforms properly, whilst the deal with Genmab should accelerate progress of the

Companies: Scancell Holdings Plc

Trinity Delta

25 Oct 22

Trinity Delta Lighthouse: Scancell

Trinity Delta view: The deal with Genmab for a GlyMab antibody brings a well-regarded, highly experienced antibody expert as a partner. Importantly it is a strong external endorsement of Scancell’s in-house antibody capabilities. The total deal terms of up to $624m in potential milestones, plus royalties, could be material for Scancell if one or more products are developed and commercialised; Genmab has a proven track record of successful clinical development. The deal also reduces the developme

Companies: Scancell Holdings Plc

Trinity Delta

15 Jun 22

Hybridan Small Cap Feast 15/06/2022

Dish of the day Joiners: Silverwood Brands (AQSE:SLWD), has been re-admitted onto the Access Segment of the AQSE Growth Market following the acquisition of Balmonds Skincare Limited by way of a signed share purchase agreement. Leavers: River and Mercantile Group has left the Main Market following a reverse takeover by AssetCo (AIM:ASTO). Marshall Motors has left AIM. Ocean Outdoor has left the Main Market. What’s cooking in the IPO kitchen? LifeSafe Holdings, a fire safety technology business wi

Companies: BSE TYM DSG SCLP KOD NAH REDX TRAC NSCI ORCA

Hybridan